Iza-Bren Significantly Improves Overall and Progression-Free Survival in Triple-Negative Breast Cancer and Esophageal Cancer SystImmune, Inc., a clinical-stage biotechnology company focused on developing innovative cancer therapies, and Bristol Myers Squibb have announced encouraging results from two pivotal Phase 3 clinical…
Incyte Reports Positive Phase 3 frontMIND Results for Tafasitamab Plus Lenalidomide Added to R-CHOP in First-Line DLBCL and HGBL Incyte Corporation (Nasdaq: INCY) has announced positive results from the pivotal Phase 3 frontMIND trial evaluating tafasitamab (Monjuvi®/Minjuvi®) in combination with…
C2N Diagnostics and SouthGenetics Partner to Expand Access to Alzheimer’s Blood Biomarker Testing Across Latin America and the Caribbean C2N Diagnostics, LLC, a specialty diagnostics company focused on advancing blood-based biomarker testing for neurodegenerative diseases, has announced a strategic collaboration…
Qurient Doses First Patient in Phase 2 Trial of Mocaciclib for CDK4/6 Inhibitor-Resistant HR-Positive Breast Cancer Qurient Co., Ltd. has announced a major clinical development milestone with the dosing of the first patient in a Phase 2 study evaluating mocaciclib…
Vertex’s Biologics License Application for Povetacicept Accepted by FDA, Advancing Potential New Treatment for IgA Nephropathy Vertex Pharmaceuticals has reached an important regulatory milestone in its efforts to expand into kidney disease treatment, announcing that the U.S. Food and Drug…
Corcept Therapeutics Reports Statistically Significant Overall Survival Benefit for Lifyorli in Platinum-Resistant Ovarian Cancer at ASCO 2026 Corcept Therapeutics Incorporated, a commercial-stage biopharmaceutical company focused on discovering and developing therapies that modulate the effects of cortisol, has announced compelling new…
Bristol Myers Squibb’s Mezigdomide Combo Shows Strong Phase 3 Success in Relapsed Multiple Myeloma at ASCO 2026 Bristol Myers Squibb has announced encouraging late-breaking results from the Phase 3 SUCCESSOR-2 clinical trial evaluating its investigational CELMoD therapy mezigdomide in combination…
PanTher Therapeutics Advances PTM-101 with Phase 1b Dose Escalation Completion in Pancreatic Cancer and Appoints Oncology Veteran Tim Clackson to Board PanTher Therapeutics, a clinical-stage biotechnology company developing implant-based localized cancer therapies, has announced a key clinical and corporate milestone…
Meiji Seika Pharma Invests in Global Health Security Fund to Advance Pandemic Preparedness and Infectious Disease Innovation Meiji Seika Pharma Co., Ltd., one of Japan’s leading pharmaceutical companies with a long-standing focus on infectious disease research and development, has announced…
Pfizer and Innovent Biologics Forge Major Global Oncology Partnership to Advance Next-Generation Cancer Medicines Pfizer Inc. and Innovent Biologics have announced a landmark strategic global licensing and collaboration agreement aimed at accelerating the discovery, development, and commercialization of a new…
ReST Therapeutics Receives FDA IND Clearance for PTSD Therapy RST-101 ReST Therapeutics announced that the U.S. Food and Drug Administration has accepted the company’s Investigational New Drug (IND) application for RST-101, its lead investigational therapy being developed for the early…
Draig Therapeutics Highlights Positive Phase 1 DT-101 Results at ASCP Annual Meeting American Society for Clinical Psychopharmacology served as the stage for new clinical and translational data from Draig Therapeutics, which unveiled encouraging findings from its Phase 1 clinical development…